Maximum Strength Zantac

Manufacturer: Boehringer Ingelheim Pharmaceuticals Inc. | Patheon Manufacturing Services LLC | Boehringer Ingelheim Promeco S.A de C.V.
Effective date: 2019-11-20
Label type: HUMAN OTC DRUG LABEL
Version: 6
Source: legacy-cache
Hydrated at: 2026-08-01 23:58:17

Label at a glance#

ProductMaximum Strength Zantac

Active ingredientRANITIDINE HYDROCHLORIDE

Label structure11 sections

Indications and uses

relieves heartburn associated with acid indigestion and sour stomach prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods and beverages

Dosage and administration

adults and children 12 years and over: to relieve symptoms, swallow 1 tablet with a glass of water to prevent symptoms, swallow 1 tablet with a glass of water 30 to 60 minutes before eating food or drinking beverages that cause heartburn can be used up to twice daily (do not take more than 2 tablets in 24 hours) children under 12 years: ask a doctor

Contacts and useful links#

PhoneLabel contact1-888-285-9159

Websitewww.zantacotc.com

www.zantacotc.com

Label contents#

Full prescribing information#

Drug Facts

OTC - ACTIVE INGREDIENT SECTION

*Active ingredient (in each tablet)*	*Purpose*
Ranitidine 150 mg (as ranitidine hydrochloride 168 mg)......................................................................................................	Acid reducer

Uses

OTC - PURPOSE SECTION

relieves heartburn associated with acid indigestion and sour stomach
prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods and beverages

Warnings

WARNINGS SECTION

Allergy alert: Do not use if you are allergic to ranitidine or other acid reducers

Do not use

if you have trouble or pain swallowing food, vomiting with blood, or bloody or black stools. These may be signs of a serious condition. See your doctor.
with other acid reducers
if you have kidney disease, except under the advice and supervision of a doctor

Ask a doctor before use if you have

OTC - ASK DOCTOR SECTION

had heartburn over 3 months. This may be a sign of a more serious condition.
heartburn with lightheadedness, sweating or dizziness
chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness
frequent chest pain
frequent wheezing, particularly with heartburn
unexplained weight loss
nausea or vomiting
stomach pain

Stop use and ask a doctor if

OTC - STOP USE SECTION

your heartburn continues or worsens
you need to take this product for more than 14 days

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

Directions

DOSAGE & ADMINISTRATION SECTION

adults and children 12 years and over:
- to relieve symptoms, swallow 1 tablet with a glass of water
- to prevent symptoms, swallow 1 tablet with a glass of water 30 to 60 minutes before eating food or drinking beverages that cause heartburn
- can be used up to twice daily (do not take more than 2 tablets in 24 hours)
children under 12 years: ask a doctor

Other information

OTHER SAFETY INFORMATION

do not use if printed foil under bottle cap is open or torn (bottles)
do not use if individual blister unit is open or torn (blisters)
do not use if individual foil packet is open or torn (pouch)
store at 20º-25ºC (68º-77ºF)
avoid excessive heat or humidity
this product is sodium and sugar free

Inactive ingredients

INACTIVE INGREDIENT SECTION

hypromellose, magnesium stearate, microcrystalline cellulose, synthetic red iron oxide, titanium dioxide, triacetin

Questions?

OTC - QUESTIONS SECTION

Call 1-888-285-9159 (English/Spanish) M – F, 8:30 – 5 EST, or visit www.zantacotc.com

Read the directions, consumer information leaflet and warnings before use. Keep the carton. It contains important information.

Boehringer Ingelheim Consumer Health Care Products
Division of Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877
Copyright © 2015, Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.
Product of Spain. Manufactured in Mexico.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Zantac 150 mg - 24 Count Blister Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Zantac 150 mg - 65 Count Bottle Carton

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
0597-0121-24	EA - Each	0597-0121	f5302b60-3cb0-4798-945e-392de372d736	1	2012-07-24
0597-0121-50	EA - Each	0597-0121	52fe690d-3c38-4b1f-8236-f13a7248401d	1	2012-07-24
0597-0121-68	EA - Each	0597-0121	8b633da4-67ec-4fdf-9e51-981627caa051	1	2012-07-24
0597-0121-90	EA - Each	0597-0121	bdb0cd21-0472-4295-ae3f-73af5ddcb287	1	2012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	SPL version
ranitidine hydrochloride	ACTIVE INGREDIENT	BK76465IHM	4
ranitidine	ACTIVE MOIETY	884KT10YB7	4
cellulose, microcrystalline	INACTIVE INGREDIENT	OP1R32D61U	4
ferric oxide red	INACTIVE INGREDIENT	1K09F3G675	4
hypromelloses	INACTIVE INGREDIENT	3NXW29V3WO	4
magnesium stearate	INACTIVE INGREDIENT	70097M6I30	4
titanium dioxide	INACTIVE INGREDIENT	15FIX9V2JP	4
triacetin	INACTIVE INGREDIENT	XHX3C3X673	4

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

Maximum Strength Zantac
ranitidine
HYPROMELLOSES
MAGNESIUM STEARATE
CELLULOSE, MICROCRYSTALLINE
FERRIC OXIDE RED
TITANIUM DIOXIDE
TRIACETIN
RANITIDINE HYDROCHLORIDE

NDC Codes#

Product NDC, Package NDC table
Product NDC	Package NDC
0597-0121	0597-0121-06, 0597-0121-50, 0597-0121-08, 0597-0121-09, 0597-0121-24, 0597-0121-38, 0597-0121-64, 0597-0121-68, 0597-0121-80, 0597-0121-82, 0597-0121-94, 0597-0121-90, 0597-0121-85, 0597-0121-01, 0597-0121-78, 0597-0121-66, 0597-0121-11

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Name, UNII, Kind table
Name	UNII	Kind
HYPROMELLOSES	3NXW29V3WO	IACT
MAGNESIUM STEARATE	70097M6I30	IACT
CELLULOSE, MICROCRYSTALLINE	OP1R32D61U	IACT
FERRIC OXIDE RED	1K09F3G675	IACT
TITANIUM DIOXIDE	15FIX9V2JP	IACT
TRIACETIN	XHX3C3X673	IACT
RANITIDINE HYDROCHLORIDE	BK76465IHM	ACTIM

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 3 · 169 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredient	IID ingredient	UNII	Dosage form / route	Potency	Maximum daily exposure	Match
hypromelloses	HYPROMELLOSE	3NXW29V3WO	SYRUP / ORAL		250 mg	Exact identifier — unii candidate 27 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	CAPSULE, COATED, EXTENDED RELEASE / ORAL	NA		Exact identifier — unii candidate 40 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL		42 mg	Exact identifier — unii candidate 40 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	CREAM / TOPICAL		80 mg	Exact identifier — unii candidate 40 equally ranked IID candidates
cellulose, microcrystalline	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	TABLET, FILM COATED / ORAL		992 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
ferric oxide red	FERRIC OXIDE RED	1K09F3G675	TABLET, EXTENDED RELEASE / ORAL		7 mg	Exact identifier — unii candidate 21 equally ranked IID candidates
cellulose, microcrystalline	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	GRANULE, FOR SUSPENSION / ORAL		278 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
ferric oxide red	FERRIC OXIDE RED	1K09F3G675	TABLET, ORALLY DISINTEGRATING / ORAL		2 mg	Exact identifier — unii candidate 21 equally ranked IID candidates
magnesium stearate	MAGNESIUM STEARATE	70097M6I30	TROCHE / ORAL		315 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	FILM, SOLUBLE / BUCCAL		11 mg	Exact identifier — unii candidate 40 equally ranked IID candidates
cellulose, microcrystalline	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	TABLET, EXTENDED RELEASE / ORAL		5119 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
hypromelloses	HYPROMELLOSE	3NXW29V3WO	SUSPENSION / ORAL		305 mg	Exact identifier — unii candidate 27 equally ranked IID candidates
magnesium stearate	MAGNESIUM STEARATE	70097M6I30	SYSTEM / INTRAVITREAL	0.02 mg		Exact identifier — unii candidate 39 equally ranked IID candidates
cellulose, microcrystalline	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	GRANULE / ORAL		29520 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
magnesium stearate	MAGNESIUM STEARATE	70097M6I30	DROPS / ORAL	NA		Exact identifier — unii candidate 39 equally ranked IID candidates
magnesium stearate	MAGNESIUM STEARATE	70097M6I30	SUSPENSION / ORAL		64 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
ferric oxide red	FERRIC OXIDE RED	1K09F3G675	POWDER, FOR SUSPENSION / ORAL		1 mg	Exact identifier — unii candidate 21 equally ranked IID candidates
magnesium stearate	MAGNESIUM STEARATE	70097M6I30	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL		47 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	TABLET / ORAL		232 mg	Exact identifier — unii candidate 40 equally ranked IID candidates
cellulose, microcrystalline	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	TABLET, CHEWABLE / ORAL		1725 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	TABLET, ORALLY DISINTEGRATING / ORAL		6 mg	Exact identifier — unii candidate 40 equally ranked IID candidates
magnesium stearate	MAGNESIUM STEARATE	70097M6I30	TABLET, CHEWABLE / ORAL		127 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
ferric oxide red	FERRIC OXIDE RED	1K09F3G675	TABLET / ORAL		8 mg	Exact identifier — unii candidate 21 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	CAPSULE / ORAL		72 mg	Exact identifier — unii candidate 40 equally ranked IID candidates
hypromelloses	HYPROMELLOSE	3NXW29V3WO	GRANULE / ORAL		45 mg	Exact identifier — unii candidate 27 equally ranked IID candidates
ferric oxide red	FERRIC OXIDE RED	1K09F3G675	CAPSULE, COATED / ORAL	0.12 mg		Exact identifier — unii candidate 21 equally ranked IID candidates
ferric oxide red	FERRIC OXIDE RED	1K09F3G675	CAPSULE, COATED PELLETS / ORAL	2 mg		Exact identifier — unii candidate 21 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	POWDER / ORAL	2 mg		Exact identifier — unii candidate 40 equally ranked IID candidates
magnesium stearate	MAGNESIUM STEARATE	70097M6I30	INSERT / VAGINAL		69 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	CAPSULE, EXTENDED RELEASE / ORAL		67 mg	Exact identifier — unii candidate 40 equally ranked IID candidates
triacetin	TRIACETIN	XHX3C3X673	TABLET / ORAL		208 mg	Exact identifier — unii candidate 14 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	TABLET, DELAYED RELEASE / ORAL		66 mg	Exact identifier — unii candidate 40 equally ranked IID candidates
magnesium stearate	MAGNESIUM STEARATE	70097M6I30	CAPSULE, EXTENDED RELEASE / ORAL		117 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	SOAP / TOPICAL	1 %w/w		Exact identifier — unii candidate 40 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	FILM, SOLUBLE / ORAL		2 mg	Exact identifier — unii candidate 40 equally ranked IID candidates
ferric oxide red	FERRIC OXIDE RED	1K09F3G675	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL	0.15 mg		Exact identifier — unii candidate 21 equally ranked IID candidates
magnesium stearate	MAGNESIUM STEARATE	70097M6I30	TABLET, EXTENDED RELEASE / ORAL		173 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
hypromelloses	HYPROMELLOSE	3NXW29V3WO	TABLET, CHEWABLE / ORAL	11.8 mg		Exact identifier — unii candidate 27 equally ranked IID candidates
hypromelloses	HYPROMELLOSE	3NXW29V3WO	SYSTEM / TOPICAL		54 mg	Exact identifier — unii candidate 27 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	POWDER, FOR SUSPENSION / ORAL		297 mg	Exact identifier — unii candidate 40 equally ranked IID candidates
hypromelloses	HYPROMELLOSE	3NXW29V3WO	CAPSULE, COATED, EXTENDED RELEASE / ORAL	NA		Exact identifier — unii candidate 27 equally ranked IID candidates
hypromelloses	HYPROMELLOSE	3NXW29V3WO	JELLY / TOPICAL	NA		Exact identifier — unii candidate 27 equally ranked IID candidates
ferric oxide red	FERRIC OXIDE RED	1K09F3G675	TABLET, FILM COATED / ORAL		3 mg	Exact identifier — unii candidate 21 equally ranked IID candidates
triacetin	TRIACETIN	XHX3C3X673	CONCENTRATE / ORAL		250 mg	Exact identifier — unii candidate 14 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	OINTMENT / TOPICAL	5 %w/w		Exact identifier — unii candidate 40 equally ranked IID candidates
triacetin	TRIACETIN	XHX3C3X673	CAPSULE, EXTENDED RELEASE / ORAL		467 mg	Exact identifier — unii candidate 14 equally ranked IID candidates
triacetin	TRIACETIN	XHX3C3X673	TABLET, DELAYED RELEASE / ORAL		23 mg	Exact identifier — unii candidate 14 equally ranked IID candidates
ferric oxide red	FERRIC OXIDE RED	1K09F3G675	TABLET, FILM COATED, EXTENDED RELEASE / ORAL	3.6 mg		Exact identifier — unii candidate 21 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	SUSPENSION / ORAL		113 mg	Exact identifier — unii candidate 40 equally ranked IID candidates
magnesium stearate	MAGNESIUM STEARATE	70097M6I30	POWDER, FOR SUSPENSION / ORAL		120 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
cellulose, microcrystalline	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	TABLET / SUBLINGUAL	43.2 mg		Exact identifier — unii candidate 28 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	FILM, EXTENDED RELEASE / TRANSDERMAL	NA		Exact identifier — unii candidate 40 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	GRANULE, FOR SUSPENSION / ORAL		143 mg	Exact identifier — unii candidate 40 equally ranked IID candidates
titanium dioxide	TITANIUM DIOXIDE	15FIX9V2JP	CAPSULE, LIQUID FILLED / ORAL		12 mg	Exact identifier — unii candidate 40 equally ranked IID candidates
cellulose, microcrystalline	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	SUSPENSION, EXTENDED RELEASE / ORAL		1120 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
ferric oxide red	FERRIC OXIDE RED	1K09F3G675	TABLET / SUBLINGUAL	1 mg		Exact identifier — unii candidate 21 equally ranked IID candidates
cellulose, microcrystalline	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	POWDER, FOR SOLUTION / ORAL		690 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
hypromelloses	HYPROMELLOSE	3NXW29V3WO	TABLET, EXTENDED RELEASE / ORAL		1472 mg	Exact identifier — unii candidate 27 equally ranked IID candidates
triacetin	TRIACETIN	XHX3C3X673	SYSTEM / TRANSDERMAL	22.1 mg		Exact identifier — unii candidate 14 equally ranked IID candidates
triacetin	TRIACETIN	XHX3C3X673	CAPSULE / ORAL		13 mg	Exact identifier — unii candidate 14 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
N021698-001	ZANTAC 150	RANITIDINE HYDROCHLORIDE	EQ 150MG BASE	TABLET / ORAL		RLD	2004-08-31
N021698-002	ZANTAC 150	RANITIDINE HYDROCHLORIDE	EQ 150MG BASE	TABLET / ORAL		RLD	2007-03-13

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 86 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-09-14 22:38:34	2026-08	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`8072bd15b7f6…`
2024-05-31 18:47 UTC	2024-05	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`5c6f7cd8ea54…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2004-08-31	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`4b0b4de00fa7…`
2019-12-13 00:20 UTC	2019-12	N021698-001	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD, RS	2004-08-31	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N021698-002	ZANTAC 150	EQ 150MG BASE	TABLET / ORAL	RLD	2007-03-13	`74a2ff9319b5…`

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
b1cfa500-1895-4766-a712-34926848025e			4da36a98-7363-4a8a-9bfe-5dfa7d2e1268	2021-05-01	Warnings	Exact identifier spl set id: 4da36a98-7363-4a8a-9bfe-5dfa7d2e1268

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.